Product Images Aggrastat

Aggrastat (tirofiban hydrochloride) is for intravenous use only and comes in a single-dose vial of 5 mg per 100 mL injection. It is used in adult dosage, as indicated in the accompanying insert. The medication should be protected from light during storage and not be frozen. Any unused portion of the vial should be disposed of after use. The medication should be stored at 25°C with excursions permitted between 15-30°C (59-86°F), adhering to USP controlled room temperature guidelines. The manufacturer of the medication is Emergent BioSolutions, and it is distributed in the US by Medicure Pharma, Inc.*

PROTECT FROM LIGHT Aggrastat is an injection containing tirofiban hydrochloride. It is manufactured for Medicure International, Inc. by Emergent BioSolutions and is distributed by Medicure Pharma, Inc. The drug is stored in a single-dose vial and should be discarded after use. The usual adult dosage should be obtained from the accompanying insert, and storage instructions are available on the carton. A lot number is provided.*

AGGRASTAT (tirofiban hydrochloride) Injection is a premixed injection used for intravenous use only. Each mL contains tirofiban hydrochloride equivalent to 0.25 mg of tirofiban with several inactive ingredients. The usual adult dosage should be seen in the accompanying insert. The vial should be stored at controlled room temperature and discarded when unused. AGGRASTAT is manufactured for Medicure International, Inc by Emergent BioSolutions, and distributed by Medicure Pharma, Inc.*

This is a description of the drug Aggrastat. It is a premixed injection containing 5mg of tirofiban hydrochloride per 100mL of solution. It is designed for intravenous injection only and should be protected from light during storage. The pH may have been adjusted with hydrochloric acid and/or sodium hydroxide. The recommended adult dosage is listed in an accompanying insert. Aggrastat is manufactured for Medicure International, Inc. by Emergent BioSolutions and distributed by Medicure Pharma, Inc. It is stored at 25°C (77°F) with excursions permitted between 15-30°C (59-86°F) and should not be frozen. Unused portions should be discarded after use.*

The text contains a chart showing the results of a study comparing the risk reduction of a composite endpoint between Heparin and AGGRASTAT + Heparin after a 180-day follow-up period. AGGRASTAT + Heparin showed a 22% risk reduction (p=0.029), while Heparin showed a 19% risk reduction (p=0.024). The chart shows the study day from 30 to 180.*

This text is describing the calculation for administering a medication. The dosage of the medication is determined as 25 milligrams per kilogram of body weight. The bolus volume of the medication is given as 250 micrograms per milliliter.*

This text provides instructions on how to calculate the bolus volume in mL for administering medication based on the body weight of an individual. The formula involves multiplying 25 mg/kg by the individual's body weight in kg. The resulting dose is then given as 50 mcg/mL.*

This text provides a calculation for determining the infusion rate for individuals with a creatinine clearance greater than 60 mL/min. The formula involves multiplying 0.15 meg/kg/min by the individual's body weight in kg and 60 min/h. The resulting value is then multiplied by 50 mcg/mL to determine the infusion rate in mL/h.*

This text provides information on calculating the infusion rate for a medication when administered to a patient with a Creatinine Clearance (CrCl) > 60 mL/min. It includes the dosage of the medication in mcg/kg/min and the weight of the patient in kg. Additionally, it lists the infusion rate of the medication in mL/h when considering a concentration of 50 mcg/mL. The final output given by the calculation is 108mL/h.*

This text provides a formula to calculate the infusion rate for individuals with CrCl (creatinine clearance) less than 60 mL/min. The formula is based on the individual's body weight and recommends an infusion rate of 0.075 mcg/kg/min multiplied by body weight (kg) multiplied by 60 min/h. The result provides the infusion rate in mL/h and should not exceed 50 mcg/mL.*

GGRASTAT is a medication with a recommended usage of a calibrated infusion device for intravenous injection. It is premixed, iso-osmotic, and nonpyrogenic. Each container contains trofiban hydrochloride, sodium chloride, sodium citrate dihydrate, and dextrose solution. The usual dosage is directed by the physician. It is advised to check for minute skin by tearing or checking the bag, and if any leaks are found, discard the bag as the sterility may be impaired. GGRASTAT should not be used if there are any signs of any damage to the bag or connections. It should be stored at room temperature between 15-30C and protected from light. The medication is manufactured by Laboratorios Grifols SA in Barcelona and distributed by Medicure Pharma in the USA.*

This is a description of AGGRASTAT® (tirofiban hydrochloride) injection in a single dose container of 250 mL, recommended for use with calibrated infusion devices. Each 250 mL contains tirofiban hydrochloride equivalent to 12.5 mg tirofiban, 2.25 g sodium chloride, 135 mg sodium citrate dihydrate, 8 mg citric acid anhydrous, Water for Injection. The usual dosage is intravenously as directed by a physician. It is cautioned not to add supplementary medication, check for minute leaks by squeezing the bag firmly, and not to use in series connections. AGGRASTAT® is a registered trademark of Medicure International, Inc. The product is manufactured for Medicure International, Inc. and distributed by Medicure Pharma, Inc. The recommended storage is at 25°C (77°F) with excursions permitted between 15° 30°C (59° - 86°F) and must not freeze while protecting it from light during storage.*

This is a description of the medication AGGRASTAT, a premixed injection used with a calibrated infusion device. It is recommended to protect from light during storage and is single-dose. The medication is registered with Mediure international and contains tirofiban hydrochloride. The dosage is directed by a physician, and caution should be taken not to add supplementary medication. The storage temperature is recommended between 15-30°C and should not be frozen. There are additional details regarding storage and usage listed on the package insert.*

The text describes a medicament labeled as "AGGRASTAT", categorized as a pre-mixed injection containing "tirofiban hydrochloride" in "iso-osmotic" solution with recommended dose of "12.5 mg per 250 mL". It is advised to protect the solution from light during storage and to not add supplementary medication to it. The solution is recommended for use with calibrated infusion devices, under physician's direction. It is manufactured for and distributed by Medicure International Inc. in Princeton, NJ, USA. The text also shows the NDC code for the product and the precautions for use.*

This text provides information on the recommended usage, dosage, and storage details of Aggrastat injection medicine that is used with calibrated infusion devices to treat patients intravenously as prescribed by a physician. The medicine comes in a single-use container of 100ml and contains Tirofiban hydrochloride equivalent to § mg tirofiban. The text cautions not to add any medicines and to check for minute leaks in the container. The injection should not be used in series connections and should not be used if the solution is not clear. The recommended storage temperature is between 15-30°C, and the manufacturer is Medicure Pharma, Inc, located in Princeton, NJ.*

This is a description of the GGRASTAT® injection, a premixed drug used for intravenous infusion. The product is contained in a nonpyrogenic, sterile, and iso-osmotic single-dose container, which contains 250 mL of Tirofiban hydrochloride equivalent to 125 mg of Tirofiban. It also has other components like water for injection, sodium chloride, citric acid anhydrous, and sodium citrate dihydrate. The medication is administered intravenously as advised by a physician, and it is recommended to use calibrated infusion devices. Storage should be at a temperature between 15°C and 30°C and protected from light. Leaks should be checked, and bags discarded if found, to avoid impaired sterility. The product is manufactured by Laboratorios Grifols S.A. and distributed by Medicure Pharma,Inc. It is a documented trademark of Medicure International, Inc.*